Keywords: telogen effluvium, effluvium, stress telogen effluvium, hair loss, androgenetic alopecia
"MULTICENTER STUDY CARRIED OUT WITH A NUTRACEUTICAL IN CAPSULES AND A PHYTOTHERAPEUTIC LOTION, IN PATIENTS WITH STRESS-RELATED TELOGEN EFFLUVIUM"
Bianca Maria Piraccini, Michela Starace, Pietro Quaglino, Giuseppe Gallo and Roberta Vezzoni
Target
The objective of the study was to determine the efficacy and tolerability of an oral treatment(Restax Effluvium® cps) and a topical lotion(Restax Women’s Lotion® and Restax Men’s Lotion®), containing active nutraceutical and phytotherapeutic ingredients. The study was carried out on male and female Telogen Effluvium patients with Stress Related and lasted for 4 months, during which hair status was evaluated in a ratio of before and after treatment.
The evaluation was collected before and after the treatment through the judgment of the practitioner and the patient.
Materials and Methods
Eighty-six male and female volunteer patients with telogen effluvium with an age range of 18 to 70 years were included in the study. They were excluded from the study:
- patients with malignant neoplasms, both systemic and cutaneous, or severe systemic diseases (diabetes, cirrhosis);
- subjects who were using cosmetic or drug therapies for androgenetic alopecia at least in the 6 months before or during the study
- Those individuals with inflammatory scalp conditions or pregnant and lactating women.
Mode of intake/application: Patients were asked to take Restax Effluvium® cps, 1 tablet with lunch and 1 tablet with dinner for the first month, then 1 tablet with dinner for another 3 months, and to apply Restax Women’s Lotion® or Restax Men’s Lotion® in the mode of 15 sprays to the affected areas on alternate days at least 3 times a week for 4 months.
The composition of the nutraceutical RESTAX EFFLUVIUM® 30 cpr is as follows:
- N-Acetylcysteine 600mg
- 5-Hydroxy Tryptophan 47mg
- Biotin 500mcg
- Zinc Gluconate 7.5mg
The composition of RESTAX LOTION UOMO® 100ML is as follows:
- Dimethyl Sulfone 0.5%
- Sphinganine 0.3%
- Chasteberry 2%
- Hops 1%
- Ribes Nigrum 0.5%
- Serenoa Repens 0.5%
The composition of RESTAX WOMAN’S LOTION® 100ML is as follows:
- Dimethyl Sulfone 0.5%
- Sphinganine 0.3%
- Chasteberry 1%
- Hops 2%
- Ribes Nigrum 0.5%
Study duration: The study lasted 4 months.
CENTERS INVOLVED IN THE STUDY
- University of Bologna, Prof. Piraccini, Dr. Starace Michela.
- San Lazzaro Hospital, Turin, Prof. Pietro Quaglino, Dr. Giuseppe Gallo.
- Dr. Roberta Vezzoni
Parameters of effectiveness
We wanted to test the efficacy and tolerability of the treatment by collecting the patient’s commentary on subjective symptoms and the physician’s judgment with comparative evaluation of the clinical evolution of the pathology through different parameters performed before and after treatment. Of these patients, 30 patients underwent global photography and 10 patients underwent both global photography and video-dermatoscopy before and after treatment.
Clinical evaluation by the researcher
1)Pull test
For all patients, the pull test was evaluated with a rating scale of 0 to 5. Zero was assigned as negative, 1 as slightly positive, 2 as positive, 3 as very positive, 4 as extremely positive and 5 as strongly positive.
2)Global photography
Global photography was required on 40 patients. It consists of photographic equipment that allows standardized documentation of the hair by means of overlapping and comparable photographs. Each photograph is always taken at the same distance, with the patient in the same position, allowing objective assessment of alopecia progression or improvement.
3)Trichoscopy
Trichoscopy has been requested for 10 patients. It is performed using the Fotofinder® instrument, and the 7-point result will be evaluated at the follow-up visit:
-3 = important aggravation of hair quantity
-2 = moderate aggravation of hair quantity
-1 = slight aggravation of hair quantity
0 = stability in the amount of hair
1 = slight improvement with increase in hair quantity
2 = moderate increase in the amount of hair
3 = important increase in the amount of hair
-3 = important aggravation of hair diameter
-2 = moderate aggravation of hair diameter
-1 = slight aggravation of hair diameter
0 = stability of hair diameter
1 = slight improvement with increase in hair diameter
2 = moderate increase in hair diameter
3 = important increase in hair diameter
4)Final comprehensive evaluation
For all patients, the researcher’s evaluation of the final results was collected following this 7-point rating scale
-3 = major aggravation of hair loss
-2 = moderate aggravation of hair loss
-1 = slight aggravation of hair loss
0 = stability in hair loss
1 = slight improvement with reduction in hair loss
2 = moderate improvement with cessation of hair loss
3 = major improvement with hair regrowth
Assessment by the patient
1)Tricodynia and itching
All patients were asked to rate trichodynia and pruritus on a scale of 0 to 5. Zero was assigned as negative, 1 as slightly positive, 2 as positive, 3 as very positive, 4 as extremely positive, and 5 as strongly positive.
2)Satisfaction of overall results
The patient’s assessment of overall achievements was collected following this 5-point rating scale
0 = not at all satisfied
1 = poorly satisfied
2 = moderately satisfied
3 = definitely satisfied
4 = very satisfied
3)Product liking
At the end of the treatment, the subject was asked to give a personal evaluation, by means of a questionnaire, on the digestibility and ease of intake/application of the product and overall liking with a rating scale of 0 to 5. Zero was given as negative, 1 as slightly positive, 2 as positive, 3 as very positive, 4 as extremely positive, and 5 as strongly positive.
Results
A total of 86 patients, 76 females and 10 males, with telogen effluvium were enrolled, and 85 completed the 4 months of therapy.
The mean age of the patients was 41.5 years.
No major side effects were reported by patients. The only patient who did not complete the study had personal reasons.
Effectiveness
Clinical evaluation by the researcher
- Pull Test
Before and after 4 months of oral treatment with Restax Effluvium® cps and use of a topical lotion(Restax Women’s Lotion® or Restax Men’s Lotion®), the pull test was rated by the researcher on a scale of 0 to 5.
Zero was assigned as negative, 1 as slightly positive, 2 as positive, 3 as very positive, 4 as extremely positive and 5 as strongly positive.
The mean pull test at enrollment was 1.95, thus between slightly positive and positive. After 4 months of treatment, a significant decrease in hair loss was found in the patients, with the mean pull test reduced to 0.68 (65.27% reduction).
Trichoscopic assessment:
-Hair quantity
The mean assessment on hair quantity at time T0 of patients’ trichoscopy was made on 10 patients with a mean value of -1.7, where -2 indicates a moderate aggravation of hair quantity and -1 a mild aggravation of hair quantity.
At the follow-up trichoscopy after 4 months, 9 patients were reassessed. The mean trichoscopic value had risen to +1.9, where 1 indicates slight improvement with increase in hair quantity and 2 indicates moderate increase in hair quantity.
-Hair diameter
The mean assessment on hair quantity at time T0 of patients’ trichoscopy was evaluated on 10 patients with a mean value of -1 indicating a slight aggravation of hair diameter.
At the follow-up trichoscopy after 4 months, 9 patients were reassessed. The mean trichoscopic diameter value had risen to +1.2, where 1 indicates a slight improvement in hair hair diameter and value 2 corresponds to a moderate increase in hair diameter.
Overall final evaluation of the researcher
For all 85 patients, the researcher’s evaluation of the final results was collected following this 7-point rating scale.
The researcher estimated an average improvement of 2.27, where 2 represents a moderate improvement with cessation of hair loss and the value 3 a major improvement with hair regrowth.
Assessment by the patient
1)Tricodynia and itching
The presence of trichodynia and pruritus were evaluated before and after 4 months of treatment by the patient.
Both were rated with a score from 0 to 5. Zero was assigned as negative, 1 as slightly positive, 2 as positive, 3 as very positive, 4 as extremely positive, and 5 as strongly positive.
At the beginning of the study, trichodynia was detected in 59 patients (68.6%) with a mean value of 1.55 (between slightly positive and positive). After 4 months of treatment, a 54.14% reduction in trichodynia was detected, with a mean value of 0.71 (between negative and slightly positive).
Mean pruritus at the beginning of the study was rated a mean of 1.1 (between slightly positive and positive). After 4 months of treatment, it was reduced by 38.95%.
2)Patient’s satisfaction with the results obtained
After 4 months of treatment, patients gave an average efficacy opinion of 2.88, where value 2 indicates moderately satisfied patient and value 3 indicates definitely satisfied.
3)Product liking
On average, patients expressed an overall product liking of 3.28, where 3 indicates very positive and 4 indicates extremely positive.
The oral supplement Restax Effluvium® cps was rated excellently digestible with an average comment of 3.53, where 3 indicates very positive and 4 indicates extremely positive.
The ease of administration/taking of both the tablets and the lotion(Restax Women’s Lotion® or Restax Men’s Lotion®) was judged on average with the value of 3.52, where 3 indicates very positiveand 4 extremely positive.
4)Tolerability
All patients tolerated the treatment excellently, with no need to discontinue treatment. No episodes of gastrointestinal complaints were reported. No adverse events occurred.
Discussion and conclusions
The term alopecia refers to a range of conditions that are characterized by a quantitative reduction of hair in any region of the body that normally has it. Numerous conditions have been described that can induce a state of alopecia. Some are widely spread such as androgenetic alopecia, which is the most common cause of hair loss in men and women. This condition most affects the 35-45 age group. Recent findings on the crucial role played by androgens and the possible involvement of stem cells suggest the use of therapeutic principals capable of modifying the action of androgens on the hair follicle and the tissue response of the stem compartment. The main goals of treatment of patients with androgenetic alopecia are aimed at preventing or improving miniaturization, prolonging the anagen phase, so that normalization of the follicular cycle can be achieved.
The biological concept of Telogen effluvium (T.E.) was first introduced in 1961 by Klingam, who noted that a variety of events (toxic, infectious, and metabolic causes) altering the normal hair cycle caused sudden and massive hair loss (during the telogen phase) over the entire scalp. This generally resolved spontaneously and completely, but was a source of anxiety for patients. Clinical experience in recent years has suggested the possible existence of various forms of T.E. related to the mode of onset and clinical course, which can be distinguished into: acute, subacute and chronic.
Individuals with acute T.E. complain of conspicuous and sudden hair loss lasting 2 to 3 months, which stops spontaneously, which is generally followed by complete regrowth. Women are more likely to be affected by chronic T.E.: these describe their hair as thicker than usual before the onset of the fall. However, this condition also affects males, particularly those with androgenetic alopecia, with the mechanism of delayed telogen effluvium: the onset is frequently sudden and alarms patients by its unusual intensity. One of the symptoms that in 30 percent of cases is associated with this type of hair loss is TRICODINIA, or, as patients often call it, scalp soreness (paresthesia), likened to needle pricks. In T.E., the duration of the fall can be very variable as it can occur for a few months or up to a few years without any seasonal fluctuation or spontaneous healing.
The combination of Restax Effluvium® cps and Restax Women’s Lotion® or Restax Men’s Lotion® has been shown to be effective in the treatment of TELOGEN EFFLUVIUM STRESS CORRELATED.
N-ACETILCYSTEINE (NAC) is the precursor to GLUTATIONE, but unlike glutathione itself, it is able to cross the blood-brain barrier. At the CNS level it is then converted to glutathione, which in turn is converted to Cysteine, Glycine and Glutamate.
Cysteine dimerizes into Cystine, which is transported within astrocytes near the Accumbens Nucleus in exchange with glutamate. The increase in extracellular glutamate results in an inhibition of glutaminergic (excitatory) transmission, resulting in a predominance of GABAergic (inhibitory) transmission.
In addition, neuronal Glutathione modulates DOPAMINE release and NMDA receptor activity in the nucleus striatum and limbic system, particularly in the Nucleus Accumbens, systems that play a key role in several disorders.
In fact, Acetylcysteine has been successfully tested, in the treatment of schizophrenia, mood disorders (depression, mania), bipolar disorder, obsessive-compulsive disorder, and also in addictions, impulse control disorder such as TRICOTILLOMANIA.
NAC also has a potent antioxidant action as a glutathione precursor, so it is widely used and is being studied as a therapy to reduce the OXIDATIVE STRESS generated by the inflammatory cascade during Sars-Cov2 infection.
TRIPTOPHAN 5-HYDROXIDE is converted at the CNS level to Serotonin, a neurotransmitter implicated in the regulation of mood, sleep and appetite. Serotonin also is a precursor of MELATONIN, directly involved in the hair cycle with antiapoptotic and antioxidant effects
BIOTIN is an important coenzyme for fat and carbohydrate metabolism: its deficiency causes alopecia, thinning, and loss of natural hair color.
ZINC GLUCONATE is an essential mineral on which numerous enzymatic activities depend; its deficiency can cause hair changes including TELOGENN EFFLUVIUM. Its organic gluconate form makes it well tolerated, absorbable and bioavailable. It is also useful in sebum-regulation by reducing seborrheic dermatitis.
The Men’s Lotion differs from the Women’s Lotion in the presence of Serenoa Repens extract and also the ratio of Chasteberry to Hops is 2:1 compared to the women’s formulation where the ratio is 1:2.
Dimethyl Sulfone enhances solubilization and release of all active ingredients.
Sphinganine is a natural skin sphingolipid of fundamental importance for its biological functions. It acts physiologically on hair loss by rebalancing its life cycle, nourishing the hair follicle and improving scalp health.
Sphinganine balances the natural hair cycle and promotes the Anagen phase:
-improves the quality of the scalp and hair
– naturally promotes hair growth
-physiologically rebalances the local skin microflora
-provides building blocks such as proteins and ceramides
-improves cell renewal capacity
-rebalances the hair life cycle by physiologically inhibiting 5 alpha reductase.
Agnocaste is a progestin natural that acts physiologically on the activity of adenylyl cyclase and thus on the glycolysis of the hair follicle, reduces the duration of the Catagen-Telogen phase by helping to activate Aromatase.
Hops contain phytoestrogens that activate P-450 Aromatase, physiologically inducing Estrone synthesis and activating the Anagen phase. Hops contain, among other constituents, Hopein, a natural substance that is considered the most potent plant estrogen known today. The discovery and characterization of this molecule are quite recent and have been studied in detail by researchers at the University of Ghent (Belgium), in collaboration with King’s College London, who have succeeded in isolating the substance, defining it chemically (8-prenylna ringenin) and testing it with respect to functionality on human physiology.
Hopein has been shown to be about 100 times more active than genistein or daidzein, pharmacological preparations having the same functionality on the female organism, partly due to its high bioavailability, that is, the property of a molecule to be absorbed, metabolized and, therefore not lost from the body. It is a phytoestrogen that physiologically increases estrone levels by activating the Anagen phase.
Ribes Nigrum is a natural anti-inflammatory in that it physiologically blocks the synthesis of local pro-inflammatory cytokines.
Serenoa Repens generates a physiological blockade of 5 alpha reductase, which has a higher expression in the scalp of men than women, also reduces miniaturization and sebum formation.
Serenoa Repens counteracts the action of dihydrotestosterone in two ways: it inhibits 5 alpha reductase coenzymes 1 and 2 in both prostate and follicular cells.
It thus reduces the production of dihydrotestosterone from testosterone. It also inhibits binding between dihydrotestosterone and receptor in the pilosebaceous unit competitively: β-sitosterin binds to the receptor for dihydrotestosterone, thus preventing its action. It also acts peripheral receptor level without interfering with endocrine glands. Serenoa Repens also has a mild estrogen-like action. β-sitosterin undergoes aromatization and behaves as a weak estrogen, activating membrane adenylyl cyclase and stimulating matrix mitoses: thus contributing to Anagen maintenance and Catagen optimization.
In conclusion, Restax Effluvium® cps and the combination with Restax Women’s Lotion® or Restax Men’s Lotion® has been shown to be an effective synergistic therapy in the treatment of TELOGEN EFFLUVIUM STRESS CORRELATED in most patients.
Want to find out more about the RestaX range?
Bibliography
Abdel Fattah N, Ebrahim A, El Okda E. Lipid peroxidation/antioxidant activity in patients with alopecia areata. J Invest Dermatol. 1984 May;82(5):515-7.
Bernard BA. The life of human hair follicle revealed]. Med Sci (Paris). 2006 Feb;22(2):138-43.
Shin H. et al. – Induction of transforming growth factor-beta 1 by androgen is mediated by reactive oxygen species in hair follicle dermal papilla cells – BMB Rep. 2013; 46(9): 460-464
Seiberg M. – Age-induced hair greying – the multiple effects of oxidative stress – International Journal of Cosmetic Science, 2013, 35, 532-538
Young M et al – Promising alternative clinical uses of prostaglandin F2a analogs: Beyond the eyelashes. J Am Acad Dermatol, Published online january 16, 2015
Nieves A., Garza L.A. – Does prostaglandin D2 hold the cure to male pattern baldness? Exp Dermatol 2014 Apr;23(4):224-7
Colombe L. et al. – Prostaglandin metabolism in human hair follicle – Experimental Dermatology , Volume 16, Issue 9, pages 762-769, september 2007
Murray A. et al. – Prostaglandin-induced hair growth – Suvey of ophthalmology, volume 47, supplement 1 – august 2002
Blume-Peytavi U. et al – A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24 week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia – J. American Academy dermatology – Volume 66, number 5, 794- 800, May 2012
Naito A. et al – Lipid peroxides induce early onset of catagen phase in murine hair cycles. Int J Mol med 2008 dec;22(6):725-9
Liu N. et al – Chronic restraint stress inhibits hair growth via substance P mediated by reactive oxygen species in mice. PloS One. 2013 Apr 26;8(4):e 61574
Botchkareva N.V. et al – Apoptosis in the hair follicle. J Invest Dermatol. 2006 Feb;126(2):258-64